Cytotoxicity of a Ti(IV) compound is independent of serum proteins

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 13, 2012, Pages 5016-5021

  Tinoco, Arthur D ^a   Thomas, Horatio R ^a   Incarvito, Christopher D ^b   Saghatelian, Alan ^a   Valentine, Ann M ^b,c  

^a HARVARD UNIVERSITY   (United States)

^b YALE UNIVERSITY   (United States)

^c Temple University   (United States)

Author keywords

Albumin; Drug delivery; Metal based anticancer compounds; Transferrin

Indexed keywords

ANTINEOPLASTIC METAL COMPLEX; CITRIC ACID; N,N' BIS(2 HYDROXYBENZYL)ETHYLENEDIAMINE N,N' DIACETIC ACID; NAPHTHALENE DERIVATIVE; SERUM ALBUMIN; TITANIUM; TRANSFERRIN;

ARTICLE; CANCER CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG ANALYSIS; DRUG BIOAVAILABILITY; HUMAN; HUMAN CELL; LUNG CANCER; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN INTERACTION;

BLOOD PROTEINS; CELL DEATH; CELL LINE, TUMOR; CHELATING AGENTS; CHROMATOGRAPHY, LIQUID; CRYSTALLOGRAPHY, X-RAY; DIMETHYLFORMAMIDE; DRUG SCREENING ASSAYS, ANTITUMOR; EDETIC ACID; HUMANS; HYDROGEN-ION CONCENTRATION; MASS SPECTROMETRY; POTENTIOMETRY; SERUM ALBUMIN; SPECTROPHOTOMETRY; TITANIUM; TRANSFERRIN;

EID: 84859453673     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1119303109     Document Type: Article

References (47)

1. Rosenberg B, VanCamp L, Trosko JE, Mansour VH (1969) Platinium compounds: Anew class of potent antitumour agents. Nature 222:385-386.
2. Siddik ZH (2003) Cisplatin: Mode of cytotoxic action and molecular basis of resistance. Oncogene 22:7265-7279. (Pubitemid 37487159)
3. Caruso F, Rossi M (2004) Antitumor titanium compounds. Mini Rev Med Chem 4: 49-60. (Pubitemid 38842594)
4. Olszewski U, Hamilton G (2010) Mechanisms of cytotoxicity of anticancer titanocenes. Anticancer Agents Med Chem 10:302-311.
5. Dyson PJ, Sava G (2006) Metal-based antitumour drugs in the post genomic era. Dalton Trans 16:1929-1933. (Pubitemid 43797525)
6. IV-transferrin by cancer cells: Understanding the mechanism of action of the anticancer drug titanocene dichloride. Biochemistry 39:10023-10033.
7. Williams J, Moreton K (1980) Distribution of iron between the metal-binding sites of transferrin in human serum. Biochem J 185:483-488. (Pubitemid 10112316)
8. Li HY, Sadler PJ, Sun HZ (1996) Rationalization of the strength of metal binding to human serum transferrin. Eur J Biochem 242:387-393. (Pubitemid 26414245)
9. Tinoco AD, Valentine AM (2005) Ti(IV) binds to human serum transferrin more tightly than does Fe(III). J Am Chem Soc 127:11218-11219. (Pubitemid 41176863)
10. Aarabi MH, Mirhashemi SM, Ani M, Moshtaghie AA (2011) Comparative binding studies of titanium and iron to human serum transferrin. Asian J Biochem 6:191-199.
11. Nuevo-Ordonez Y, Montes-Bayon M, Gonzalez EB, Sanz-Medel A (2011) Titanium preferential binding sites in human serum transferrin at physiological concentrations. Metallomics 3:1297-1303.
12. Keer HN, et al. (1990) Elevated transferrin receptor content in human prostate cancer cell lines assessed in vitro and in vivo. J Urol 143:381-385. (Pubitemid 20066402)
13. Tinoco AD, Eames EV, Valentine AM (2008) Reconsideration of serum Ti(IV) transport: Albumin and transferrin trafficking of Ti(IV) and its complexes. J Am Chem Soc 130: 2262-2270. (Pubitemid 351288003)
14. Shavit M, Peri D, Melman A, Tshuva EY (2007) Antitumor reactivity of non-metallocene titanium complexes of oxygen-based ligands: Is ligand lability essential? J Biol Inorg Chem 12:825-830. (Pubitemid 47174872)
15. Gao LM, Hernandez R, Matta J, Melendez E (2007) Synthesis, Ti(IV) intake by apo transferrin and cytotoxic properties of functionalized titanocene dichlorides. J Biol Inorg Chem 12:959-967. (Pubitemid 47353542)
16. Hernandez R, et al. (2008) Structure-activity studies of Ti(IV) complexes: Aqueous stability and cytotoxic properties in colon cancer HT-29 cells. J Biol Inorg Chem 13: 685-692.
17. Tshuva EY, Ashenhurst JA (2009) Cytotoxic titanium(IV) complexes: Renaissance. Eur J Inorg Chem 2009:2203-2218.
18. Tshuva EY, Peri D (2009) Modern cytotoxic titanium(IV) complexes; Insights on the enigmatic involvement of hydrolysis. Coord Chem Rev 253:2098-2115.
19. Immel TA, Groth U, Huhn T (2010) Cytotoxic titanium salan complexes: Surprising interaction of salan and alkoxy ligands. Chemistry 16:2775-2789.
20. Tinoco AD, Eames EV, Incarvito CD, Valentine AM (2008) Hydrolytic metal with a hydrophobic periphery: Titanium(IV) complexes of naphthalene-2,3-diolate, and interactions with serum albumin. Inorg Chem 47:8380-8390.
21. Kratz F (2008) Albumin as a drug carrier: Design of prodrugs, drug conjugates and nanoparticles. J Control Release 132:171-183.
22. Ravera M, Gabano E, Baracco S, Osella D (2009) Electrochemical evaluation of the interaction between antitumoral titanocene dichloride and biomolecules. Inorg Chim Acta 362:1303-1306.
23. Pavlaki M, et al. (2009) A proposed mechanism for the inhibitory effect of the anticancer agent titanocene dichloride on tumour gelatinases and other proteolytic enzymes. J Biol Inorg Chem 14:947-957.
24. Vessieres A, et al. (2009) Proliferative and anti-proliferative effects of titanium-and iron-based metallocene anti-cancer drugs. J Organomet Chem 694:874-879.
25. Eger S, et al. (2010) Titanocene difluorides with improved cytotoxic activity. Inorg Chem 49:1292-1294.
26. Hogan M, Claffey J, Pampillon C, Watson RWG, Tacke M (2007) Synthesis and cytotoxicity studies of new dimethylamino-functionalized and azole-substituted titanocene anticancer drugs. Organometallics 26:2501-2506. (Pubitemid 46795098)
27. Peri D, Meker S, Manna CM, Tshuva EY (2011) Different ortho and para electronic effects on hydrolysis and cytotoxicity of diamino bis(phenolato) "salan" Ti(IV) complexes. Inorg Chem 50:1030-1038.
28. Manna CM, Armony G, Tshuva EY (2011) New insights on the active species and mechanism of cytotoxicity of salan-Ti(IV) complexes: A stereochemical study. Inorg Chem 50:10284-10291.
29. 2-symmetrical Ti(IV) phenolato complexes; mechanistic implications. Dalton Trans 39:1182-1184.
30. Potter GD, Baird MC, Chan M, Cole SPC (2006) Cellular toxicities of new titanocene dichloride derivatives containing pendant cyclic alkylammonium groups. Inorg Chem Commun 9:1114-1116.
31. Kaluderovic GN, et al. (2010) Synthesis, characterization and biological studies of alkenyl- substituted titanocene(IV) carboxylate complexes. Appl Organomet Chem 24: 656-662.
32. Potter GD, Baird MC, Cole SPC (2010) A new series of titanocene dichloride derivatives bearing chiral alkylammonium groups; assessment of their cytotoxic properties. Inorg Chim Acta 364:16-22.
33. Tinoco AD, Incarvito CD, Valentine AM (2007) Calorimetric, spectroscopic, and model studies provide insight into the transport of Ti(IV) by human serum transferrin. J Am Chem Soc 129:3444-3454. (Pubitemid 46449376)
34. 6). Inorg Chem 31:3737-3748.
35. x (x = 1-3) structural units. Inorg Chem 33:2462-2471.
36. Crescenzi R, Solari E, Floriani C, Chiesi-Villa A, Rizzoli C (1996) Binding of amesooctaethyl tris(pyrrole)-mono(pyridine) ligand to titanium(III) and titanium(IV): A monomeric titanium(IV) oxo bis(pyridine)-bis(pyrrole) complex derived from the C-O bond cleavage of carbon monoxide. Organometallics 15:5456-5458. (Pubitemid 126531877)
37. Hagadorn JR, Arnold J (1998) Titanium(II), -(III), and -(IV) complexes supported by benzamidinate ligands. Organometallics 17:1355-1368. (Pubitemid 128590708)
38. Guo ML, Harvey I, Campopiano DJ, Sadler PJ (2006) Short oxo-titanium(IV) bond in bacterial transferrin: A protein target for metalloantibiotics. Angew Chem Int Ed 45: 2758-2761. (Pubitemid 44099100)
39. Collins JM, Uppal R, Incarvito CD, Valentine AM (2005) Titanium(IV) citrate speciation and structure under environmentally and biologically relevant conditions. Inorg Chem 44:3431-3440. (Pubitemid 40758068)
40. Mycielska ME, et al. (2009) Citrate transport and metabolism in mammalian cells: Prostate epithelial cells and prostate cancer. Bioessays 31:10-20.
41. Birch N, Wang X, Chong HS (2006) Iron chelators as therapeutic iron depletion agents. Expert Opin Ther Patents 16:1533-1556.
42. Immel TA, Groth U, Huhn T, Ohlschlager P (2011) Titanium salan complexes displays strong antitumor properties in vitro and in vivo in mice. PLoS ONE 6::e17869.
43. Tzubery A, Tshuva EY (2011) Trans titanium(IV) complexes of salen ligands exhibit high antitumor activity. Inorg Chem 50:7946-7948.
44. Glasner H, Tshuva EY (2011) A marked synergistic effect in antitumor activity of salan titanium(IV) complexes bearing two differently substituted aromatic rings. J Am Chem Soc 133:16812-16814.
45. Jenkins BG, Armstrong E, Lauffer RB (1991) Site-specific water proton relaxation enhancement of iron(III) chelates noncovalently bound to human serum albumin. Magn Reson Med 17:164-178.
46. Kakuta K, Orino K, Yamamoto S, Watanabe K (1997) High levels of ferritin and its iron in fetal bovine serum. Comp Biochem Physiol A Physiol 118:165-169. (Pubitemid 27319811)
47. Rajan KS, Murase I, Martell AE (1969) New multidentate ligands. VII. Ethylenediamine- N,N′-diacetic-N,N′-di(methlenephosphonic)acid. J Am Chem Soc 91:4408-4412.